Why the study?
Does intra-arterial infusion of an ETA receptor blocker (BQ-123) increase forearm blood flow in obese hypertensive patients compared to normotensive controls?
Population
Hypertensive patients and normotensive control subjects, categorized by body mass index into obese…
Comparison
Intra-arterial infusion of an ETA receptor blocker vs Normotensive control subjects receiving the same…
Design
Cross-sectional
Authors
Loading...
Suggests BMI augments ETA vasoconstrictor tone in hypertension; leaves open whether endothelin blockade benefits obese patients.
Does intra-arterial infusion of an ETA receptor blocker (BQ-123) increase forearm blood flow in obese hypertensive patients compared to normotensive controls?
Increased BMI in hypertensive patients is associated with enhanced ETA-dependent vasoconstrictor activity, suggesting that targeting the endothelin-1 system may be useful in treating obesity-related hypertension.
Cardillo et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: